Evidence map›Paper›PMID 25230687›Full record

ArticleClinical and experimental nephrology2015

Outcomes of primary nephrotic syndrome in elderly Japanese: retrospective analysis of the Japan Renal Biopsy Registry (J-RBR).

Hitoshi Yokoyama, Hitoshi Sugiyama, Ichiei Narita, Takao Saito, Kunihiro Yamagata, Saori Nishio, Shouichi Fujimoto, Noriko Mori, Yukio Yuzawa, Seiya Okuda and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Identification of a NovelBioMed research international · 2019
    Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 1 country.

Hitoshi YokoyamaDivision of Nephrology, Kanazawa Medical University School of Medicine, 1-1 Daigaku, Uchinada, Ishikawa, 920-0293, Japan. hyokoyama-npr@umin.ac.ip.
Hitoshi SugiyamaDepartment of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. hitoshis@md.okayama-u.ac.jp.
Ichiei NaritaDivision of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. naritai@med.niigata-u.ac.jp.
Takao SaitoGeneral Medical Research Center, Fukuoka University School of Medicine, Fukuoka, Japan. tsaito@fukuoka-u.ac.jp.
Kunihiro YamagataDepartment of Nephrology, Faculty of Medicine, University of Tsukuba, Ibaragi, Japan. k-yamaga@md.tsukuba.ac.jp.
Saori NishioDepartment of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo, Japan. saorin@med.hokudai.ac.jp.
Shouichi FujimotoDepartment of Hemovascular Medicine and Artificial Organs, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan. fujimos@med.miyazaki-u.ac.jp.
Noriko MoriDepartment of Nephrology, Shizuoka General Hospital, Shizuoka, Japan. noriko-mori@i.shizuoka-pho.jp.
Yukio YuzawaDepartment of Nephrology, Fujita Health University School of Medicine, Nagoya, Japan. yukio.kidney@gmail.com.
Seiya OkudaDivision of Nephrology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan. seokuda-circ@umin.ac.jp.
Shoichi MaruyamaDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan. marus@med.nagoya-u.ac.jp.
Hiroshi SatoClinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan. hsymhs2i@m.tohoku.ac.jp.
Yoshihiko UedaDepartment of Pathology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan. yoshi@dokkyomed.ac.jp.
Hirofumi MakinoDepartment of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. makino@md.okayama-u.ac.jp.
Seiichi MatsuoDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan. smatsuo@med.nagoya-u.ac.jp.
Nagoya University · JPOkayama University · JPDokkyo Medical University · JPFujita Health University · JPFukuoka University · JPHokkaido University · JPKanazawa Medical University · JPKurume University · JPNiigata University · JPShizuoka General Hospital · JPTohoku University · JPUniversity of Tsukuba · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThere are very little data available regarding nephrotic syndrome (NS) in elderly (aged ≥65 years) Japanese. The aim of this study was to examine the causes and outcomes of NS in elderly patients who underwent renal biopsies between 2007 and 2010. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: From July 2007 to June 2010, all of the elderly (aged ≥65 years) Japanese primary NS patients who underwent native renal biopsies and were registered in the Japan renal biopsy registry (J-RBR; 438 patients including 226 males and 212 females) were identified. From this cohort, 61 patients [28 males and 33 females including 29, 19, 6, 4, and 3 patients with membranous nephropathy (MN), minimal change nephrotic syndrome (MCNS), focal segmental glomerulosclerosis (FSGS), membranoproliferative glomerulonephritis (MPGN), and other conditions, respectively] were registered from the representative multi-centers over all districts of Japan, and analyzed retrospectively. The treatment outcome was assessed using proteinuria-based criteria; i.e., complete remission (CR) was defined as urinary protein level of <0.3 g/day or g/g Cr, and incomplete remission type I (ICR-I) was defined as urinary protein level of <1.0-0.3 g/day or g/g Cr, and renal dysfunction was defined as a serum creatinine (Cr) level of 1.5 times the baseline level.

resultsIn this elderly primary NS cohort, MN was the most common histological type of NS (54.8 %), followed by MCNS (19.4 %), FSGS (17.4 %), and MPGN (8.4 %). Of the patients with MN, MCNS, or FSGS, immunosuppressive therapy involving oral prednisolone was performed in 25 MN patients (86.2 %), 18 MCNS patients (94.7 %), and all 6 FSGS patients (100 %). CR was achieved in all 19 (100 %) MCNS patients. In addition, CR and ICR-I were achieved in 16 (55.2 %) and 18 (62.1 %) MN patients and 4 (66.7 %) and 5 (83.3 %) FSGS patients, respectively. There were significant differences in the median time to CR among the MCNS, FSGS, and MN patients (median: 26 vs. 271 vs. 461 days, respectively, p < 0.001), and between the elderly (65-74 years, n = 7) and very elderly (aged ≥75 years, n = 12) MCNS patients (7 vs. 22 days, p = 0.037). Relapse occurred in two (6.9 %) of the MN and nine (47.4 %) of the MCNS patients. Renal dysfunction was observed in five (7.2 %) of the MN patients. Serious complications developed in eight (14.8 %) patients, i.e., two (3.7 %) patients died, four (7.4 %, including three MCNS patients) were hospitalized due to infectious disease, and two (3.7 %) developed malignancies. The initiation of diabetic therapy was necessary in 14 of the 61 patients (23.0 %) with much higher initial steroid dosage.

conclusionRenal biopsy is a valuable diagnostic tool for elderly Japanese NS patients. In this study, most of elderly primary NS patients respond to immunosuppressive therapy with favorable clinical outcomes. On the other hand, infectious disease is a harmful complication among elderly NS patients, especially those with MCNS. In future, modified clinical guidelines for elderly NS patients should be developed.

Indexed as

AgedAged, 80 and overBiopsyCreatinineCyclophosphamideCyclosporineFemaleFollow-Up StudiesGlomerulonephritisGlomerulonephritis, MembranoproliferativeGlomerulonephritis, MembranousGlomerulosclerosis, Focal SegmentalHumansImmunosuppressive AgentsJapanKidneyCreatinineCyclophosphamideCyclosporineImmunosuppressive AgentsMethylprednisolonemizoribineMycophenolic AcidPrednisoloneRibonucleosidesComplicationElderlyImmunosuppressive therapyJapaneseNephrotic syndromeOutcome

Identifiers

PMID25230687
OpenAlexW1981972239

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.